Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Registry ID

EUCTR2014-003609-14

Source registry

EUCTR

Phase

PHASE3

Sponsor

CSL Behring

Last update

2026-08-16

Conditions

• Primary Immune Deficiency

Summary

To assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).

Related clinical trials

• Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
• Biologics And Clinical Immunology Cohort at Sinai
• COVID-19 in PID Survey

View on source registry